Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.31 |
| ▸ | PGR | P06401 | 2/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 4/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407668 | 0.89 | CYP3A4 (0.45) | CYP3A4CRBNMETBRD4JAK2 | |
| SCHEMBL3406008 | 0.87 | CYP3A4 (0.59) | CYP3A4CRBNMETBRD4JAK2 | |
| SCHEMBL861445 | 0.86 | CYP3A4 (0.44) | CYP3A4CRBNMETJAK2JAK1 | |
| SCHEMBL3401591 | 0.84 | CYP3A4 (0.33) | CYP3A4MET | |
| SCHEMBL859842 | 0.84 | CYP3A4 (0.45) | CYP3A4CRBNMETNR3C1BRD4 | |
| SCHEMBL861440 | 0.83 | CYP3A4 (0.43) | CYP3A4CRBNMETJAK2JAK1 | |
| SCHEMBL859888 | 0.82 | CYP3A4 (0.43) | CYP3A4CRBNMETBRD4JAK2 | |
| SCHEMBL13030236 | 0.81 | CRBN (0.41) | CYP3A4CRBNMETJAK2JAK1 | |
| SCHEMBL2618845 | 0.80 | CRBN (0.44) | CYP3A4CRBNMETJAK2JAK1 | |
| SCHEMBL13030249 | 0.79 | CRBN (0.41) | CYP3A4CRBNMETJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-11-25 | — | — | US | claimed |
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, POLR2B | CYP3A4 302/4885CRBN 1212/4885MET 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.